Epilepsy & Seizures

Filter Your Results

 

News

 

Phase 3 Trial of Low-Dose Fenfluramine for Lennox-Gastaut Syndrome Is Enrolling Patients

Tuesday, September 04, 2018—In a phase 2 open-label study of the orphan drug fenfluramine (ZX008; Zogenix, Emeryville, CA) for treatment of patients with Lennox-Gastaut Syndrome (LGS) refractory to treat…

Stiripentol Approved by FDA for Treatment of Dravet Syndrome

Friday, August 24, 2018—The Food and Drug Administration (FDA) has approved stiripentol (Diacomit; Biocodex, Gentilly, France) as an adjunct to clobazam for the treatment of seizures associated with …

New Drug Application Accepted for Midazolam Nasal Spray for Treating Patients with Acute Repetitive Seizures

Monday, August 13, 2018—The Food and Drug Administration (FDA) has accepted a new drug application (NDA) filing for midazolam nasal spray (USL261; UCB, Atlanta, GA) for the treatment of persons with …

Folic Acid During Pregnancy for Women Taking Antiepileptic Drugs May Improve Language Development for Their Children

Saturday, August 04, 2018—A study published in Neurology evaluated the relationship between language delays in children born to women taking antiepileptic drugs (AEDs) with and without folic acid suppl…

Breaching the Blood-Brain Barrier: A Potential New Treatment Modality

Monday, July 30, 2018—In a small, yet groundbreaking, clinical trial, MR-guided focused ultrasound (MRgFUS) (ExablateNeuro; Insightec, Miami FL) was used to open the blood-brain barrier (BBB) safel…

Significant Seizure Reduction in Persons With Dravet Syndrome With ZX008 in Phase 3 Trial

Thursday, July 12, 2018—Adjunctive treatment of persons with Dravet syndrom with the investigational compound, low-dose fenfluramine hydrochloride (ZX008; Zogenix, Emeryville, CA), has been shown to …

Epidiolex Approved for Treatment of Dravet and Lennox-Gastaut Syndromes

Tuesday, June 26, 2018—Yesterday, the Food and Drug Administration (FDA) approved cannabidiol (CBD) oral solution (Epidiolex; GW Research, Carlsbad, CA) for the treatment of seizures associated with…

Medtronic Deep Brain Stimulation Clinician Programmer Receives FDA Approval

Wednesday, June 13, 2018—Medtronic announced that the Food and Drug Administration (FDA) had recently approved its Deep Brain Stimulation (DBS) Clinician Programmer and Activa Programming Application.…

 
 

Contact Info

For advertising rates and opportunities:
Wendy Terry
Publisher
217-652-3859
wterry@bmctoday.com

About Practical Neurology

Launched in 2002, Practical Neurology is a publication uniquely dedicated to presenting current approaches to patient management, synthesis of emerging research and data, and analysis of industry news with a goal to facilitate practical application and improved clinical practice for all neurologists. Our straightforward articles give neurologists tools they can immediately put into practice.

 
  • BRYN MAWR COMMUNICATIONS III, LLC